Bank of America Downgrades Achillion Pharmaceuticals from Buy to Underperform, Lowers PO from $11 to $10

by Web Master, Benzinga Editor

February 7, 2012 6:42 AM | 3 seconds read | Make a Comment

Limited upside seen after M&A speculations doubling share prices.

Posted In: Downgrades Price Target Analyst Ratings Bank of America

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.